Zacks Investment Research on MSN
Pfizer's mixed phase III data for Sigvotatug Vedotin in NSCLC
Pfizer PFE has announced top-line data from a late-stage study which evaluated its investigational antibody-drug conjugate ...
Pfizer Inc. (NYSE: PFE) today announced topline results from the Phase 3 SigVie-002 study (previously known as Be6A Lung-01) evaluating sigvotatug vedotin, an investigational, potential first-in-class ...
The drug, acquired in Pfizer's $43 billion purchase of Seagen, did not outlast standard chemotherapy in a 703-patient study ...
Earlier this week, Pfizer reported that its Phase 3 SigVie-002 trial of sigvotatug vedotin in previously treated non-squamous ...
Asianet Newsable on MSN
PFE stock reacts to mixed topline results for Seagen-origin cancer drug
In the overall population, sigvotatug vedotin did not demonstrate a statistically significant improvement in overall survival ...
Bengaluru: Pfizer said its drug for a type of lung cancer missed the main goal of improving survival in patients ...
One of the antibody-drug conjugates at the heart of Pfizer's $43 billion acquisition of Seagen three years ago has failed a ...
Pfizer announced that a late-stage trial in lung cancer for a Seagen-derived ADC, sigvotatug vedotin, has failed. Phase I ...
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced topline results from the Phase 3 SigVie-002 study (previously known as Be6A Lung-01) evaluating sigvotatug vedotin, an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results